SeqLL Inc (NASDAQ:SQL) announced the establishment of a two-year Cooperative Research and Development Agreement (CRADA) with the Federal Bureau of Investigation (FBI) of the U.S. Department of Justice. The partnership will evaluate the forensic capabilities of SeqLL’s True Single Molecule Sequencing (tSMS®) platform and determine if it can produce an assay for body fluid identification without compromising traditional analysis. This is one of the first times the FBI is using CRADA to develop laboratory capabilities. Both SeqLL and the FBI Laboratory Division are eager to work together and advance the FBI’s mission through shared resources and expertise. The CEO and founder of SeqLL expressed excitement to demonstrate how single-molecule, PCR-free approaches are ideal for the forensic space.
SeqLL Inc. (“SeqLL”) is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple “omics” fields. The Company leverages its expertise with the True Single Molecule Sequencing (“tSMS®”) platform to empower scientists and researchers with improved genetic tools to better understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with today’s precision medicine.